VYNE Therapeutics Inc. (VYNE) Misses Q1 EPS by 159c

VYNE Therapeutics Inc. (NASDAQ: VYNE) reported Q1 EPS of ($1.74), $1.59 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $100 thousand versus the consensus estimate of $300 thousand.

For earnings history and earnings-related data on VYNE Therapeutics Inc. (VYNE) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• Motorsport Games Inc. (MSGM) Tops Q2 EPS by 33c